New biomarker predicts breast cancer relapse
Researchers from Virginia Commonwealth University Massey Cancer Center have discovered a new biomarker related to the body’s immune system that can predict a breast cancer patient’s risk of cancer recurrence. This breakthrough may lead to new genetic testing that further personalizes breast cancer care.
New combination therapy eradicates prostate cancer in vivo
In their study, published in the journal Proceedings of the National Academy of Sciences, prostate cancer growth in mice with functioning immune systems was inhibited by sensitizing the cancer cells with the drug Sabutoclax (BI-97C1) and using UTMD technology to deliver a viral gene therapy that expresses the genemda-7/IL-24. This powerful new approach to treating prostate cancer builds upon prior studies by principle investigator Paul B. Fisher, M.P.H., Ph.D., Thelma Newmeyer Corman Endowed Chair in Oncology Research at VCU Massey (photo on left). Fisher is professor and chair of the Department of Human and Molecular Genetics in the VCU School of Medicine, and director of the VCU Institute of Molecular Medicine.
Discovery in liver cancer cells provides new target for drugs
Researchers at Virginia Commonwealth University Massey Cancer Center and the VCU Institute of Molecular Medicine (VIMM) have discovered a novel mechanism in gene regulation that contributes to the development of a form of liver cancer called hepatocellular carcinoma. Currently, there is virtually no effective treatment for HCC, and this breakthrough identifies a promising new target for therapeutic intervention.
VCU Massey Cancer Center first to combine targeted agents to kill multiple myeloma cells
Scientists at Virginia Commonwealth University Massey Cancer Center have developed a novel treatment strategy for multiple myeloma that pairs two targeted agents to kill cancer cells. The study's findings, published in today's edition of the journal Blood, are the first to demonstrate the synergistic, anti-myeloma effects of this combination regimen both in vitro and in vivo.
Researcher receives NIH grant to study patient recruitment and consent in tissue donation
Nationally recognized expert on decision-making in organ and tissue donation Laura Siminoff, Ph.D., received a $283,000 grant from the National Institutes of Health to support her contribution to the NIHs newly launched Genotype-Tissue Expression Project. The Genotype-Tissue Expression Project is designed to understand how genetic variation may control gene activity and its relationship to disease. It will generate data about how gene expression is regulated in different organs in the human body, which will then serve as a resource for researchers across the country to study inherited susceptibility to illness and establish a tissue bank for biological studies down the road.